The approval was based on phase 3 data from the randomized, double-blind, placebo-controlled CAHtalyst adult study and CAHtalyst pediatric study.
A turbulent 2024 for Neurocrine is ending on a high note, after the biotech won FDA approval to treat congenital adrenal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback